Our studies in lung adenocarcinoma suggest that SGLT2 is expressed in the earliest stages of cancer development, and pre-malignant lesions are exquisitely sensitive to SGLT2is because they do not express glucose transporters of the GLUT family. This evidence concerns the gene SLC2A1 and cancer.